Christie Lau
0000-0003-4008-386X
8 papers found
Refreshing results…
Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
Missing publications? Search for publications with a matching author name.